Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
73.25 USD +0.33% Intraday chart for Gilead Sciences, Inc. +0.22% -9.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Xilio Shares Take Flight Premarket After Gilead Deal DJ
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall MT
Gilead Says FDA Approves New Drug Application for Potential Hep-B Treatment for Smaller Children MT
Gilead Says FDA Expands Approval of Chronic Hep-B Infection Treatment for Use in Kids DJ
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12 MT
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six CI
Xilio Therapeutics Plans Private Placement, Job Cuts DJ
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program DJ
Xilio Therapeutics, Inc. announced that it has received $13.5 million in funding from Gilead Sciences, Inc. CI
Gilead Sciences Completes $4.3 Billion Cymabay Acquisition MT
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc.. CI
Gilead Sciences Receives a Shareholder Proposal from John Chevedden CI
Gilead Sciences Receives a Shareholder Proposal from David Bahnsen CI
Gilead Sciences Receives a Shareholder Proposal from Jing Zhao CI
Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024 CI
Transcript : Gilead Sciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Transcript : Gilead Sciences, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 10:00 AM
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires MT
Health Care Up as Sector Gathers Upward Momentum -- Health Care Roundup DJ
Merck, Gilead Sciences Report Positive Data From Phase 2 Trial of Islatravir, Lenacapavir Combination in HIV MT
Gilead, Merck Report Positive Phase 2 Data on Weekly Oral HIV Combo DJ
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 CI
Gilead Sciences, Merus Collaborate to Discover New Potential Cancer Therapies MT
Gilead, Merus to Collaborate on Trispecific Antibody Research DJ
Gilead Sciences, Inc. and Merus N.V. Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers CI
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
73.25 USD
Average target price
86.45 USD
Spread / Average Target
+18.02%
Consensus
  1. Stock
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq
  4. News Gilead Sciences, Inc.
  5. Earnings Reaction History: Gilead Sciences, 63.6% Follow-Through Indicator, 3.0% Sensitive